Global Depression Drug Market is forecasted to reach $18 billion by 2024; growing at a CAGR of 2.6% from 2016 to 2024. Depression has occurred as one of the most common yet serious mental disorders among people globally. Depression is caused by amalgamation of genetics, biological, environment and psychological factors. According to WHO published in 2016, about 350 million people have been affected and depression can lead to suicide. Over 800000 people die due to suicide every year, making it the second leading cause of death in 15-29 year olds. Depression is more common in women than men. Depression drugs mechanism includes fixing the chemical imbalance, especially, lack of serotonin in the brain. Even though effective treatments are available, many individuals with depression do not have access to treatment or do not take treatment, mainly due to absence of information and social stigma.

Increasing geriatric population, rising knowledge regarding depression among people and growing number of generic drug market are likely to fuel the growth of the market. Moreover, support from government organizations could also support the growth of market. However, lack of resources, trained healthcare providers and social stigma could hinder the growth of market. Furthermore, research and development and Untapped markets could provide an opportunity for the market in upcoming years.

The market is segmented based on the product type, application and geography. Product type is further segmented into Tetracyclic Antidepressants, Serotonin-Norepinephrine Inhibitors, Selective Serotonin Reuptake Inhibitors, Tricyclice Antidepressants, Benzodiazepines, Monoamine Oxidase Inhibitors, Atypical Antipsychotics, and others. Furthermore, application is segmented into clinics and hospitals and research centers. Based on geography, the depression drug market is segmented into North America, Europe, Asia-Pacific and Rest of World. The U.S., Mexico and Canada are covered under North America wherein Europe covers France, Germany, UK, Spain and rest of Europe. Asia-Pacific covers China, India, Japan, South Korea and Rest of Asia Pacific. Rest of the World (RoW) covers South America, Middle East and Africa.

The key takeaways from the report:
The report will provide detailed analysis of Depression Drugs Market with respect to major segments such as product type and application
The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
Comprehensive analysis of market dynamics including factors and opportunities is inluded in the report
An exhaustive regional analysis of Depression Drugs Market will be provided in the report
Profile of the key players in the Depression Drugs Market will be provided, which include key financials, product & services, new developments and business strategies
Scope of Depression Drugs Market
Product Type Segments
Tetracyclic Antidepressants
Serotonin-Norepinephrine Inhibitors
Selective Serotonin Reuptake Inhibitors
Tricyclice Antidepressants
Benzodiazepines
Monoamine Oxidase Inhibitors
Atypical Antipsychotics
Others
Application Segments
Clinics and Hospitals
Research centres
Geographical Segments
North America
US
Canada
Mexico
Europe
Germany
France
United Kingdom
Spain
Others
Asia-Pacific
China
India
Japan
South Korea
Others
RoW
South America
Middle East
Africa